Arnold Gutierrez1, Kevin M Creehan1, Michael A Taffe2. 1. Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. 2. Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. Electronic address: mtaffe@ucsd.edu.
Abstract
BACKGROUND: The ongoing crisis related to non-medical use of opioids makes it of continued importance to understand the risk factors for opioid addiction, the behavioral and neurobiological consequences of opioid exposure and to seek potential avenues for therapy. Pre-clinical rodent models have been critical to advancing understanding of opioid consequences for decades, but have been mostly limited to drug delivery by injection or by oral dosing. Inhalation, a significant route for many human users, has not been as well-established. METHOD: We adapted an e-cigarette based exposure system, previously shown efficacious for delivery of other drugs to rats, to deliver heroin vapor. Effectsin vivo were assessed in male and female Sprague-Dawley rats using a warm-water assay for anti-nociception and an implanted radiotelemetry system for evaluating changes in body temperature and spontaneous activity rate. RESULTS: Inhalation of vapor created by heroin 100 mg/mL in the propylene glycol (PG) vehicle significantly slowed tail-withdrawal from a 52 °C water bath, bi-phasically altered activity, and increased temperature in male and female rats. Inhalation of heroin 50 mg/mL for 15 min produced significant effects, as the lower bound on efficacy, whereas inhalation of heroin 100 mg/mL for 30 min produced robust effects across all endpoints and groups. CONCLUSIONS: This work shows that e-cigarette devices deliver psychoactive doses of heroin to rats, using concentrations of ∼50-100 mg/mL and inhalation durations of 15-30 min. This technique may be useful to assess the health consequences of inhaled heroin and other opioid drugs.
BACKGROUND: The ongoing crisis related to non-medical use of opioids makes it of continued importance to understand the risk factors for opioid addiction, the behavioral and neurobiological consequences of opioid exposure and to seek potential avenues for therapy. Pre-clinical rodent models have been critical to advancing understanding of opioid consequences for decades, but have been mostly limited to drug delivery by injection or by oral dosing. Inhalation, a significant route for many human users, has not been as well-established. METHOD: We adapted an e-cigarette based exposure system, previously shown efficacious for delivery of other drugs to rats, to deliver heroin vapor. Effectsin vivo were assessed in male and female Sprague-Dawley rats using a warm-water assay for anti-nociception and an implanted radiotelemetry system for evaluating changes in body temperature and spontaneous activity rate. RESULTS: Inhalation of vapor created by heroin 100 mg/mL in the propylene glycol (PG) vehicle significantly slowed tail-withdrawal from a 52 °C water bath, bi-phasically altered activity, and increased temperature in male and female rats. Inhalation of heroin 50 mg/mL for 15 min produced significant effects, as the lower bound on efficacy, whereas inhalation of heroin 100 mg/mL for 30 min produced robust effects across all endpoints and groups. CONCLUSIONS: This work shows that e-cigarette devices deliver psychoactive doses of heroin to rats, using concentrations of ∼50-100 mg/mL and inhalation durations of 15-30 min. This technique may be useful to assess the health consequences of inhaled heroin and other opioid drugs.
Authors: Christian Montanari; Leslie K Kelley; Tony M Kerr; Maury Cole; Nicholas W Gilpin Journal: Psychopharmacology (Berl) Date: 2019-11-23 Impact factor: 4.530
Authors: Maria Mavrikaki; Marco Pravetoni; Sarah Page; David Potter; Elena Chartoff Journal: Psychopharmacology (Berl) Date: 2017-01-27 Impact factor: 4.530
Authors: Timothy G Freels; Lydia N Baxter-Potter; Janelle M Lugo; Nicholas C Glodosky; Hayden R Wright; Samantha L Baglot; Gavin N Petrie; Zhihao Yu; Brian H Clowers; Carrie Cuttler; Rita A Fuchs; Matthew N Hill; Ryan J McLaughlin Journal: J Neurosci Date: 2020-01-17 Impact factor: 6.167
Authors: M Jerry Wright; Deepshikha Angrish; Shawn M Aarde; Deborah J Barlow; Matthew W Buczynski; Kevin M Creehan; Sophia A Vandewater; Loren H Parsons; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe Journal: PLoS One Date: 2012-08-31 Impact factor: 3.240